spironolactone/PD - Search Results

Year	Number of Results
1962	1
1963	1
1964	1
1965	11
1966	23
1967	27
1968	38
1969	59
1970	60
1971	62
1972	71
1973	79
1974	79
1975	61
1976	77
1977	74
1978	72
1979	69
1980	63
1981	44
1982	50
1983	54
1984	52
1985	39
1986	45
1987	43
1988	55
1989	37
1990	44
1991	48
1992	39
1993	33
1994	57
1995	30
1996	27
1997	30
1998	46
1999	30
2000	58
2001	60
2002	59
2003	111
2004	112
2005	116
2006	107
2007	103
2008	98
2009	116
2010	132
2011	116
2012	136
2013	140
2014	110
2015	112
2016	125
2017	100
2018	77
2019	79
2020	69
2021	56
2022	27

1

Spironolactone.

Carone L, Oxberry SG, Twycross R, Charlesworth S, Mihalyo M, Wilcock A. Carone L, et al. J Pain Symptom Manage. 2017 Feb;53(2):288-292. doi: 10.1016/j.jpainsymman.2016.12.320. Epub 2016 Dec 23. J Pain Symptom Manage. 2017. PMID: 28024992 Free article. Review.

2

Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.

Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C. Lainscak M, et al. Int J Cardiol. 2015 Dec 1;200:25-9. doi: 10.1016/j.ijcard.2015.05.127. Epub 2015 May 21. Int J Cardiol. 2015. PMID: 26404748 Review.

3

Spironolactone for treatment of female pattern hair loss.

Burns LJ, De Souza B, Flynn E, Hagigeorges D, Senna MM. Burns LJ, et al. J Am Acad Dermatol. 2020 Jul;83(1):276-278. doi: 10.1016/j.jaad.2020.03.087. Epub 2020 Apr 5. J Am Acad Dermatol. 2020. PMID: 32259535 No abstract available.

4

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.

Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White WB, Williams B. Agarwal R, et al. Lancet. 2019 Oct 26;394(10208):1540-1550. doi: 10.1016/S0140-6736(19)32135-X. Epub 2019 Sep 15. Lancet. 2019. PMID: 31533906 Clinical Trial.

5

Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.

Santos J, Planas R, Pardo A, Durández R, Cabré E, Morillas RM, Granada ML, Jiménez JA, Quintero E, Gassull MA. Santos J, et al. J Hepatol. 2003 Aug;39(2):187-92. doi: 10.1016/s0168-8278(03)00188-0. J Hepatol. 2003. PMID: 12873814 Clinical Trial.

6

Spironolactone.

Ochs HR, Greenblatt DJ, Bodem G, Smith TW. Ochs HR, et al. Am Heart J. 1978 Sep;96(3):389-400. doi: 10.1016/0002-8703(78)90052-2. Am Heart J. 1978. PMID: 356569 Review. No abstract available.

7

Spironolactone.

[No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risk Chem Hum. 1980;24:259-73. IARC Monogr Eval Carcinog Risk Chem Hum. 1980. PMID: 7009396 Review. No abstract available.

8

Spironolactone and breast cancer: Fear not!

Heymann WR. Heymann WR. J Am Acad Dermatol. 2020 Oct;83(4):1008-1009. doi: 10.1016/j.jaad.2020.07.104. Epub 2020 Jul 29. J Am Acad Dermatol. 2020. PMID: 32738426 No abstract available.

9

Use of spironolactone to treat acne in adolescent females.

Roberts EE, Nowsheen S, Davis DMR, Hand JL, Tollefson MM, Wetter DA. Roberts EE, et al. Pediatr Dermatol. 2021 Jan;38(1):72-76. doi: 10.1111/pde.14391. Epub 2020 Oct 3. Pediatr Dermatol. 2021. PMID: 33009838

10

Efficacy and safety profile of oral spironolactone use for androgenic alopecia: A systematic review.

James JF, Jamerson TA, Aguh C. James JF, et al. J Am Acad Dermatol. 2022 Feb;86(2):425-429. doi: 10.1016/j.jaad.2021.07.048. Epub 2021 Aug 2. J Am Acad Dermatol. 2022. PMID: 34352345 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results